The authors report that BRAF/VEGFA targeting reverses immune cell exclusion by increasing the infiltration of CD8 T cells and M1–macrophages, allowing remodeling of the tumor microenvironment and sensitizing melanoma cells to immune checkpoint blockade. The gene discussed is CD8A; the disease is neoplasm.